Emmanuel Ligner, CEO of self-described bioprocess “critical actor” Cytiva talks us through the changing biomanufacturing landscape and unveils his firmâ€™s sustainability report in the latest BioProcess Insider Expression Platform podcast.
In 2021, Cytiva launched a survey measuring industryâ€™s confidence in the biopharma space. Focusing across five pillars â€“ supply chain resilience, talent pool, the R&D ecosystem, manufacturing agility, and government policy and regulation â€“ theÂ Biopharma Resilience IndexÂ averaged an overall score of 6.6 out of 10 in 2021.
Feedback from 2022â€™s survey showed â€śCOVID was a wake-up call,â€ť Emmanuel Ligner told us at BIO in San Diego last month. â€śSuddenly people realized we need to do something different; we need to pay more attention to the supply chain. We also saw governments reacting very well in many countries, and that was a very positive thing. Overall, 63% said [COVID] was a wakeup call and I think that was good for the industry.â€ť
Ligner also spoke about his firmâ€™s sustainability efforts, citing a recently published report on the issue.